Genotech Statistics
Total Valuation
Genotech has a market cap or net worth of KRW 6.13 billion.
| Market Cap | 6.13B |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Genotech has 5.60 million shares outstanding.
| Current Share Class | 5.60M |
| Shares Outstanding | 5.60M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 48.66% |
| Owned by Institutions (%) | n/a |
| Float | 2.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.84 |
| PB Ratio | 1.28 |
| P/TBV Ratio | 1.29 |
| P/FCF Ratio | 48.86 |
| P/OCF Ratio | 16.23 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.99, with a Debt / Equity ratio of 1.85.
| Current Ratio | 0.99 |
| Quick Ratio | 0.49 |
| Debt / Equity | 1.85 |
| Debt / EBITDA | n/a |
| Debt / FCF | 70.91 |
| Interest Coverage | -2.64 |
Financial Efficiency
Return on equity (ROE) is -25.60% and return on invested capital (ROIC) is -4.56%.
| Return on Equity (ROE) | -25.60% |
| Return on Assets (ROA) | -4.12% |
| Return on Invested Capital (ROIC) | -4.56% |
| Return on Capital Employed (ROCE) | -9.99% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.47 |
| Inventory Turnover | 2.13 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.39% in the last 52 weeks. The beta is 0.31, so Genotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | -21.39% |
| 50-Day Moving Average | 1,132.06 |
| 200-Day Moving Average | 1,332.27 |
| Relative Strength Index (RSI) | 47.07 |
| Average Volume (20 Days) | 55 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genotech had revenue of KRW 7.28 billion and -1.32 billion in losses. Loss per share was -280.00.
| Revenue | 7.28B |
| Gross Profit | 962.09M |
| Operating Income | -1.01B |
| Pretax Income | -1.32B |
| Net Income | -1.32B |
| EBITDA | -347.19M |
| EBIT | -1.01B |
| Loss Per Share | -280.00 |
Balance Sheet
The company has 1.21 billion in cash and 8.89 billion in debt, giving a net cash position of -7.68 billion or -1,371.07 per share.
| Cash & Cash Equivalents | 1.21B |
| Total Debt | 8.89B |
| Net Cash | -7.68B |
| Net Cash Per Share | -1,371.07 |
| Equity (Book Value) | 4.80B |
| Book Value Per Share | 1,017.52 |
| Working Capital | -55.69M |
Cash Flow
In the last 12 months, operating cash flow was 377.41 million and capital expenditures -252.05 million, giving a free cash flow of 125.36 million.
| Operating Cash Flow | 377.41M |
| Capital Expenditures | -252.05M |
| Free Cash Flow | 125.36M |
| FCF Per Share | 22.39 |
Margins
Gross margin is 13.21%, with operating and profit margins of -13.90% and -18.14%.
| Gross Margin | 13.21% |
| Operating Margin | -13.90% |
| Pretax Margin | -18.14% |
| Profit Margin | -18.14% |
| EBITDA Margin | -4.77% |
| EBIT Margin | -13.90% |
| FCF Margin | 1.72% |
Dividends & Yields
Genotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.92% |
| Shareholder Yield | -9.92% |
| Earnings Yield | -21.57% |
| FCF Yield | 2.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genotech has an Altman Z-Score of -0.11 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.11 |
| Piotroski F-Score | 3 |